Sébastien Violot

Dr. Sébastien Violot

Microbiology and Molecular Structural Biology, CNRS-University of Lyon UMR5086, Lyon, Auvergne-Rhône-Alpes, France
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2009 in FEBS Letters
Verified
Journal Article
Closed access
PCPhilippe Carpentier
Philippe Carpentier
SVSébastien Violot
Sébastien Violot
LBLaurent Blanchoin
Laurent Blanchoin
DBDominique Bourgeois
Dominique Bourgeois

1 May 2005 in Journal of Molecular Biology
Verified
Journal Article
Closed access
SVSébastien Violot
Sébastien Violot
NANushin Banu Helene Aghajari
Nushin Banu Helene Aghajari
MCMirjam Czjzek
Mirjam Czjzek
GFGeorges Feller
Georges Feller
GSGuillaume K. Sonan
Guillaume K. Sonan
VRVeronique Receveur-Brechot
Veronique Receveur-Brechot

10 July 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
SVSébastien Violot
Sébastien Violot
PCPhilippe Carpentier
Philippe Carpentier
LBLaurent Blanchoin
Laurent Blanchoin
DBDominique Bourgeois
Dominique Bourgeois

1 December 2009 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
VAVirgile Adam
Virgile Adam
PCPhilippe Carpentier
Philippe Carpentier
SVSébastien Violot
Sébastien Violot
MLMickaël Lelimousin
Mickaël Lelimousin
CDClaudine Darnault
Claudine Darnault
DBDominique Bourgeois
Dominique Bourgeois

1 December 2003 in Journal of Virology
Verified
Journal Article
Open access
PDF file
SVSébastien Violot
Sébastien Violot
SHSaw See Hong
Saw See Hong
DRDina Rakotobe
Dina Rakotobe
CPCaroline Petit
Caroline Petit
BGBernard Gay
Bernard Gay
PBPierre Boulanger
Pierre Boulanger
Human EED, a member of the superfamily of WD-40 repeat proteins and of the Polycomb group proteins, has been identified as a cellular partner of the human immunodeficiency virus type 1 (HIV-1) matrix (MA) protein (R. Peytavi et al., J. Biol. Chem. 274:1635-1645, 1999). In the present study, EED was found to interact with HIV-1 integrase (IN) both in vitro and in vivo in yeast. In vitro, data from mutagenesis studies, pull-down assays, and phage biopanning suggested that EED-binding site(s) are located in the C-terminal domain of IN, between residues 212 and 264. In EED, two putative discrete IN-binding sites were mapped to its N-terminal moiety, at a distance from the MA-binding site, but EED-IN interaction also required the integrity of the EED last two WD repeats. EED showed an apparent positive effect on IN-mediated DNA integration reaction in vitro, in a dose-dependent manner. In situ analysis by immunoelectron microscopy (IEM) of cellular distribution of IN and EED in HIV-1-infected cells (HeLa CD4 + cells or MT4 lymphoid cells) showed that IN and EED colocalized in the nucleus and near nuclear pores, with maximum colocalization events occurring at 6 h postinfection (p.i.). Triple colocalizations of IN, EED, and MA were also observed in the nucleoplasm of infected cells at 6 h p.i., suggesting the ocurrence of multiprotein complexes involving these three proteins at early steps of the HIV-1 virus life cycle. Such IEM patterns were not observed with a noninfectious, envelope deletion mutant of HIV-1.

3 August 2012 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
NFNisrine Falah
Nisrine Falah
RMRoland Montserret
Roland Montserret
VLVirginie Lelogeais
Virginie Lelogeais
ISIsabelle Schuffenecker
Isabelle Schuffenecker
LBLina bruno
Lina bruno
SVSébastien Violot
Sébastien Violot
Human enterovirus 71 (EV-71), a member of the Enterovirus genus, constitutes a major public health issue in the Asia-Pacific region, where it is associated with several severe neurological complications. There is currently no effective vaccine or antiviral against EV-71. The aim of this study was to determine whether the six amino acid peptide LVLQTM, which was previously shown to inhibit human rhinovirus (HRV) 2A protease (2Apro) activity in vitro and HRV replication in vivo in mice, could be of more general use against enteroviruses and more particularly against EV-71. To investigate whether the LVLQTM peptide was a pseudosubstrate of EV-71 2Apro, a recombinant luciferase containing the LVLQTM sequence was designed so that recognition of this sequence by 2Apro led to luciferase activation. Direct interaction between EV-71 2Apro and the LVLQTM peptide was further confirmed by isothermal titration calorimetry. We then tested the effects of the peptide on EV-71 2Apro cleavage activity and EV-71 replication in HeLa cells. We showed that the LVLQTM peptide behaved as an effective substrate analogue of EV-71 2Apro, which binds into the active site of the protease with a dissociation rate constant of 9.6 μM. Moreover, LVLQTM significantly inhibited eIF4G cleavage activity of 2Apro as well as EV-71 replication in HeLa cells. This study demonstrates that the LVLQTM peptide that has previously been shown to inhibit HRV replication is also an effective inhibitor of EV-71 2Apro and therefore of EV-71 replication, opening new doors in the development of new antivirals against EV-71.